We read with great interest the recent article by Bowers et al 1 dealing with the role of calcitonin gene-related peptide (CGRP) in hypertension-induced renal damage. The results of their study demonstrated that the deoxycorticosterone (DOC)-salt hypertensive ␣-CGRP knockout (KO) mice displayed markedly enhanced and progressive renal damage and expression of inflammatory markers in the immunohistochemical investigation. In addition, they indicated that the DOC-salt hypertensive ␣-CGRP KO mice exhibited elevated urinary biomarkers of oxidative stress and a marked reduction in kidney function compared with the DOCsalt wild-type mice. The authors proposed that sensory nerves, via ␣-CGRP, might be renoprotective against hypertensioninduced damage.
Response
In response to Dr Tsuda's letter to the editor with regard to our article, "Role of Calcitonin Gene-Related Peptide in Hypertension-Induced Renal Damage," 1 we would like to express our appreciation for Tsuda's comments. These comments were focused on the possible involvement of the sympathetic nervous system in the renal damage observed in the DOC-salt hypertension-induced ␣-calcitonin gene-related peptide (␣-CGRP) knockout (KO) mouse model. Specifically, Tsuda's question was whether changes in the activity of the sympathetic nervous system might be correlated with the magnitude of renal damage in the DOC-salt hypertensive ␣-CGRP KO mice compared with their wild-type (WT) counterparts used in our study. Tsuda correctly describes several lines of evidence demonstrating that ␣-CGRP can inhibit norepinephrine release in the central nervous system 2, 3 and peripheral tissues 4 and postulated that the lack of ␣-CGRP could produce sympathetic hyperactivity, thereby contributing to the observed renal damage described in our article. In this report, we stated that there are 3 possible mechanisms that may underlie our observations. The first is the higher absolute mean arterial blood pressures in the DOC-salt hypertensive ␣-CGRP KO mice compared with the hypertensive WT animals. The second is a direct effect of the lack of ␣-CGRP, and the third is that permanent deletion of the ␣-CGRP gene could significantly alter the activities of other neurohumoral systems that regulate blood pressure and contribute to hypertension-induced end organ damage, such as the sympathetic nervous system and the renin-angiotensin system. We did, in fact, specifically site studies reporting that in the absence of hypertension producing protocols, ␣-CGRP KO mice displayed significant increases in the activities of the sympathetic nervous system 5 and the renin-angiotensin system. 6 Indeed, equal weight was given to each of the 3 possible mechanisms because the experimental design of our study did not allow us to differentiate between them.
The first priority of our laboratory is to investigate the most crucial question arising from this study, which is the role of the blood pressure differential between the DOC-salt hypertensive ␣-CGRP and WT mice on the severity of the renal damage. This was done by decreasing the blood pressure (as measured by telemetric recording) in the KO mice by the administration of hydralazine in the drinking water. The results from our initial studies will be presented at the American Heart Association 59th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research in September. Once this series of experiments is completed, we will assess the participation of
